[1]
Okamura, K. et al. 2025. Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity. Journal of Clinical Medicine Research. 16, 10 (Jan. 2025), 509–517. DOI:https://doi.org/10.14740/jocmr6058.